ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 028,34
-1,11%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Amneal Pharmaceuticals Holding Co (AMRX)

  7. Amneal Pharmaceuticals Holding Co (AMRX) Actualités

AMRX Amneal Pharmaceuticals Holding Co

5,87
0,00 (0,00%)
26 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Amneal Pharmaceuticals Holding Co AMRX NYSE Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 5,87 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
5,87 5,87
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
24/4/202414:00BWAmneal Announces U.S. FDA Approval of Over-the-Counter..
16/4/202414:00BWAmneal Launches PEMRYDI RTU®, the First Ready-to-Use Version..
10/4/202414:00BWAmneal to Report First Quarter 2024 Results on May 3, 2024
28/3/202421:05BWAmneal to Ring the Nasdaq Closing Bell on April 2, 2024
25/3/202421:05BWAmneal Receives U.S. FDA Approval for Ciprofloxacin and..
22/3/202413:01EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/3/202413:01EDGAR2Form DEF 14A - Other definitive proxy statements
06/3/202423:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202412:13EDGAR2Form 8-K - Current report
01/3/202412:00BWAmneal Reports Fourth Quarter and Full Year 2023 Financial..
29/2/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202414:00BWAmneal Enters into Exclusive European Licensing Agreement..
13/2/202414:00BWAmneal to Participate at Upcoming Investor Conference
08/2/202422:05GLOBEAmneal Announces Complete Response Resubmission for IPX203..
31/1/202422:05BWAmneal to Report Fourth Quarter and Full Year 2023 Results..
10/1/202414:00BWAmneal Launches Complex Generic Fluorometholone Ophthalmic..
04/1/202422:05BWAmneal Launched Record Number of 39 New Retail and..
26/12/202322:10EDGAR2Form 25 - Notification of the removal from listing and..
26/12/202322:05EDGAR2Form 8-A12B - Registration of securities [Section 12(b)]
21/12/202314:00BWAmneal to Participate at the 42nd Annual J.P. Morgan..
15/12/202322:15EDGAR2Form 8-K - Current report
15/12/202322:06EDGAR2Form 8-K/A - Current report: [Amend]
15/12/202322:05BWAmneal Announces Move to Nasdaq
07/12/202314:00BWAmneal and BIAL Announce U.S. Licensing Agreement for..
01/12/202322:15EDGAR2Form SC 13D/A - General statement of acquisition of..
01/12/202322:15EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
01/12/202314:00BWAmneal Expands Portfolio with Addition of Icosapent Ethyl..
20/11/202312:07EDGAR2Form 15-12G - Securities registration termination [Section..
09/11/202300:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202300:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202300:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202300:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202300:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202323:15EDGAR2Form S-8 POS - Securities to be offered to employees in..
08/11/202323:13EDGAR2Form POS AM - Post-Effective amendments for registration..
08/11/202323:12EDGAR2Form POS AM - Post-Effective amendments for registration..
08/11/202323:07EDGAR2Form SC 13D/A - General statement of acquisition of..
08/11/202323:05EDGAR2Form SC 13D/A - General statement of acquisition of..
08/11/202323:03EDGAR2Form SC 13D/A - General statement of acquisition of..
08/11/202322:59EDGAR2Form SC 13D/A - General statement of acquisition of..
08/11/202322:55EDGAR2Form SC 13D/A - General statement of acquisition of..
08/11/202313:40EDGAR2Form 8-K12B - Notification that a class of securities of..
07/11/202312:21EDGAR2Form 8-K - Current report
07/11/202312:00BWAmneal Reports Third Quarter 2023 Financial Results
03/11/202313:00BWAmneal to Participate at Upcoming Investor Conferences
23/10/202322:16EDGAR2Form 8-K - Current report
23/10/202322:05BWAmneal Reports Certain Preliminary Third Quarter 2023..

Dernières Valeurs Consultées

NYSE
AMRX
Amneal Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés